Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR: p-AKT ratio predicts erlotinib sensitivity in human Non-small Cell Lung Cancer (NSCLC) cells expressing wild-type EGFR gene

Tianhong Li, Yi He Ling, Roman Perez-Soler

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

INTRODUCTION: This study was undertaken to identify molecular determinants of tumor dependency on the epidermal growth factor receptor (EGFR) signaling pathway for predicting clinical benefit from erlotinib monotherapy in non-small cell lung cancer (NSCLC) patients with tumors expressing wild-type EGFR gene. METHODS: The effect of erlotinib on the total and phosphorylated protein expression of EGFR and key downstream signaling molecules was determined by immunoblots in a panel of NSCLC cells expressing wild-type EGFR gene. The parameters that correlate with cell sensitivity and resistance to erlotinib was analyzed. RESULTS: Individual assessment of total or phosphorylated protein expression of EGFR or a downstream signaling molecule does not correlate with sensitivity to erlotinib in these NSCLC tumors. Resistance of NSCLC cells to erlotinib is associated with failed inhibition of at least one phosphorylated downstream signaling molecule. The dependency of NSCLC cells on the activated EGFR axis was measured by the ratio of p-EGFR to a phosphorylated downstream protein. A high ratio should indicate that activation of a downstream signaling molecule primarily results from the activation of upstream EGFR; and a low ratio should indicate that activation of a downstream signaling molecule primarily results from the activation of a upstream receptors other than EGFR. The p-EGFR:p-AKT ratio was 10-fold higher in erlotinib-sensitive cells than erlotinib-resistant cells (p = 0.03). It was the best predictor of erlotinib sensitivity among all parameters analyzed in this panel of NSCLC cell lines. CONCLUSIONS: The p-EGFR:p-AKT ratio deserves further investigation as a predictive parameter for clinical response to erlotinib in NSCLC tumors expressing wild-type EGFR gene.

Original languageEnglish (US)
Pages (from-to)643-647
Number of pages5
JournalJournal of Thoracic Oncology
Volume3
Issue number6
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

erbB-1 Genes
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Neoplasms
Erlotinib Hydrochloride
Proteins
Critical Pathways
Cell Line

Keywords

  • EGFR
  • Erlotinib
  • NSCLC
  • Small molecule tyrosine kinase inhibitor
  • Wild-type EGFR gene

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

@article{2418816c1b904c1ab163778971c22156,
title = "Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR: p-AKT ratio predicts erlotinib sensitivity in human Non-small Cell Lung Cancer (NSCLC) cells expressing wild-type EGFR gene",
abstract = "INTRODUCTION: This study was undertaken to identify molecular determinants of tumor dependency on the epidermal growth factor receptor (EGFR) signaling pathway for predicting clinical benefit from erlotinib monotherapy in non-small cell lung cancer (NSCLC) patients with tumors expressing wild-type EGFR gene. METHODS: The effect of erlotinib on the total and phosphorylated protein expression of EGFR and key downstream signaling molecules was determined by immunoblots in a panel of NSCLC cells expressing wild-type EGFR gene. The parameters that correlate with cell sensitivity and resistance to erlotinib was analyzed. RESULTS: Individual assessment of total or phosphorylated protein expression of EGFR or a downstream signaling molecule does not correlate with sensitivity to erlotinib in these NSCLC tumors. Resistance of NSCLC cells to erlotinib is associated with failed inhibition of at least one phosphorylated downstream signaling molecule. The dependency of NSCLC cells on the activated EGFR axis was measured by the ratio of p-EGFR to a phosphorylated downstream protein. A high ratio should indicate that activation of a downstream signaling molecule primarily results from the activation of upstream EGFR; and a low ratio should indicate that activation of a downstream signaling molecule primarily results from the activation of a upstream receptors other than EGFR. The p-EGFR:p-AKT ratio was 10-fold higher in erlotinib-sensitive cells than erlotinib-resistant cells (p = 0.03). It was the best predictor of erlotinib sensitivity among all parameters analyzed in this panel of NSCLC cell lines. CONCLUSIONS: The p-EGFR:p-AKT ratio deserves further investigation as a predictive parameter for clinical response to erlotinib in NSCLC tumors expressing wild-type EGFR gene.",
keywords = "EGFR, Erlotinib, NSCLC, Small molecule tyrosine kinase inhibitor, Wild-type EGFR gene",
author = "Tianhong Li and Ling, {Yi He} and Roman Perez-Soler",
year = "2008",
month = "6",
doi = "10.1097/JTO.0b013e3181753b24",
language = "English (US)",
volume = "3",
pages = "643--647",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

TY - JOUR

T1 - Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR

T2 - p-AKT ratio predicts erlotinib sensitivity in human Non-small Cell Lung Cancer (NSCLC) cells expressing wild-type EGFR gene

AU - Li, Tianhong

AU - Ling, Yi He

AU - Perez-Soler, Roman

PY - 2008/6

Y1 - 2008/6

N2 - INTRODUCTION: This study was undertaken to identify molecular determinants of tumor dependency on the epidermal growth factor receptor (EGFR) signaling pathway for predicting clinical benefit from erlotinib monotherapy in non-small cell lung cancer (NSCLC) patients with tumors expressing wild-type EGFR gene. METHODS: The effect of erlotinib on the total and phosphorylated protein expression of EGFR and key downstream signaling molecules was determined by immunoblots in a panel of NSCLC cells expressing wild-type EGFR gene. The parameters that correlate with cell sensitivity and resistance to erlotinib was analyzed. RESULTS: Individual assessment of total or phosphorylated protein expression of EGFR or a downstream signaling molecule does not correlate with sensitivity to erlotinib in these NSCLC tumors. Resistance of NSCLC cells to erlotinib is associated with failed inhibition of at least one phosphorylated downstream signaling molecule. The dependency of NSCLC cells on the activated EGFR axis was measured by the ratio of p-EGFR to a phosphorylated downstream protein. A high ratio should indicate that activation of a downstream signaling molecule primarily results from the activation of upstream EGFR; and a low ratio should indicate that activation of a downstream signaling molecule primarily results from the activation of a upstream receptors other than EGFR. The p-EGFR:p-AKT ratio was 10-fold higher in erlotinib-sensitive cells than erlotinib-resistant cells (p = 0.03). It was the best predictor of erlotinib sensitivity among all parameters analyzed in this panel of NSCLC cell lines. CONCLUSIONS: The p-EGFR:p-AKT ratio deserves further investigation as a predictive parameter for clinical response to erlotinib in NSCLC tumors expressing wild-type EGFR gene.

AB - INTRODUCTION: This study was undertaken to identify molecular determinants of tumor dependency on the epidermal growth factor receptor (EGFR) signaling pathway for predicting clinical benefit from erlotinib monotherapy in non-small cell lung cancer (NSCLC) patients with tumors expressing wild-type EGFR gene. METHODS: The effect of erlotinib on the total and phosphorylated protein expression of EGFR and key downstream signaling molecules was determined by immunoblots in a panel of NSCLC cells expressing wild-type EGFR gene. The parameters that correlate with cell sensitivity and resistance to erlotinib was analyzed. RESULTS: Individual assessment of total or phosphorylated protein expression of EGFR or a downstream signaling molecule does not correlate with sensitivity to erlotinib in these NSCLC tumors. Resistance of NSCLC cells to erlotinib is associated with failed inhibition of at least one phosphorylated downstream signaling molecule. The dependency of NSCLC cells on the activated EGFR axis was measured by the ratio of p-EGFR to a phosphorylated downstream protein. A high ratio should indicate that activation of a downstream signaling molecule primarily results from the activation of upstream EGFR; and a low ratio should indicate that activation of a downstream signaling molecule primarily results from the activation of a upstream receptors other than EGFR. The p-EGFR:p-AKT ratio was 10-fold higher in erlotinib-sensitive cells than erlotinib-resistant cells (p = 0.03). It was the best predictor of erlotinib sensitivity among all parameters analyzed in this panel of NSCLC cell lines. CONCLUSIONS: The p-EGFR:p-AKT ratio deserves further investigation as a predictive parameter for clinical response to erlotinib in NSCLC tumors expressing wild-type EGFR gene.

KW - EGFR

KW - Erlotinib

KW - NSCLC

KW - Small molecule tyrosine kinase inhibitor

KW - Wild-type EGFR gene

UR - http://www.scopus.com/inward/record.url?scp=44649203417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649203417&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181753b24

DO - 10.1097/JTO.0b013e3181753b24

M3 - Article

C2 - 18520805

AN - SCOPUS:44649203417

VL - 3

SP - 643

EP - 647

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -